Comparative Analytical Study of Intravitreal Triamcinolone Acetonide Versus Bevacizumab in Managing Diabetic Macular Edema: Insights From a Tertiary Eye Care Facility in India

Both IVTA and IVB effectively enhance visual acuity and reduce macular edema in diabetic retinopathy. IVB demonstrates superior short-term gains in visual acuity (over one to three months). In contrast, IVTA is more effective in decreasing CFT, thanks to its broader mechanism of action, including inhibition of vascular endothelial growth factor and cytokines. The longer half-life of IVTA provides more sustained anatomical benefits but is associated with higher IOP, necessitating careful monitoring. Conversely, IVB presents fewer complications, making it a safer option for certain patients. Treatment choice should consider the patient's risk profile, balancing efficacy with potential side effects.